• Non-myeloablative, so-called mini transplant (microtransplantation) procedures, have been developed requiring smaller doses of preparative chemotherapy and radiation therapy, allowing HSCT to be conducted in the elderly and other patients who would otherwise be considered too weak to withstand a conventional treatment regimen. (wikipedia.org)
  • Autologous HSCT following high-dose chemotherapy, the standard treatment for adult patients with relapsed HL, is also effective in paediatric patients, but randomized trials showing its superiority to conventional therapy are lacking. (nih.gov)
  • The mediannumber of chemotherapy regimens was 2 after tositumomab/iodine-131 tositumomaband prior to HSCT (range: 1-4). (cancernetwork.com)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, HSCT or radiotherapy prior to entering this study. (sparkcures.com)
  • Prophylactic antibiotics are often used in pediatric patients for the treatment of acute myeloid leukemia (AML) and relapsed acute lymphoblastic leukemia (ALL), and for those undergoing hematopoietic stem cell transplant (HSCT) who are receiving intensive chemotherapy. (jhoponline.com)
  • 3 Patients receiving intensive chemotherapy for AML or ALL and those undergoing HSCT have an increased risk for serious bacterial infections. (jhoponline.com)
  • In recent years, especially after the advent of reduced intensity conditioning in the late 1990s, allogeneic HSCT is increasingly used in older patients and as an effective salvage strategy for patients with lymphoma or myeloma not responding to chemotherapy or autologous HSCT. (longdom.org)
  • [ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (medscape.com)
  • Autologous transplants have the advantage of lower risk of infection during the immune-compromised portion of the treatment, since the recovery of immune function is rapid. (wikipedia.org)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • For this research, Prof. Inglese and her staff examined the information of 79 individuals with lively secondary progressive MS who acquired autologous hematopoietic stem cell transplants (AHSCT). (getnom.net)
  • Haematopoietic stem cell transplants have been performed in more than 1 500 000 patients (both autologous and allogeneic) to date.1 Although haematological cancers remain the main indication, haematopoietic stem cell transplants are increasingly considered in the treatment of non-malignant disorders and genetic diseases such as haemoglobinopathies (sickle cell anaemia, thalassaemia) that can benefit greatly from this type of transplant. (who.int)
  • Alternative to varicella-zoster immune globulin (VZIG) for postexposure prophylaxis of VZV infection † in HSCT recipients. (drugs.com)
  • Although long-term prophylaxis not routinely recommended for prevention of recurrent VZV infections in HSCT recipients, such prophylaxis may be considered in those with severe, long-term immunodeficiency. (drugs.com)
  • Six patients relapsed, includingall five autologous and one allogeneic recipients. (cancernetwork.com)
  • The other three allogeneic recipients died from either graft-vs-hostdisease, relapse, or acetaminophen-induced hepatic necrosis. (cancernetwork.com)
  • In the analysis, the investigators included 200 patients made up of 63 allogeneic-HSCT recipients, 74 autologous-HSCT recipients, and 63 HSCT donors. (contagionlive.com)
  • The study found that rates of latent tuberculosis were 17% in all-HSCT recipients, 24% in auto-HSCT, and 39% in donors. (contagionlive.com)
  • To our knowledge, this is the first study that evaluates the prevalence of LTBI among HSCT recipients in a Latin American country where TB is endemic," the investigators wrote. (contagionlive.com)
  • G-CSF is a commonly used mobilizing agent for practically all autologous and a majority of allogeneic HSCTs and is known to increase CD34+ concentration. (bdbiosciences.com)
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
  • Data suggest that young patients with recurring disease following autologous HSCT, as well as some patients with multiple relapses and selected patients with refractory lymphoma, might benefit from allogeneic HSCT, but relapse remains the major challenge. (nih.gov)
  • Antifungal prophylaxis with an oral triazole or parenteral echinocandin is recommended for patients who are at risk for profound, protracted neutropenia, such as most patients with acute myeloid leukemia/myelodysplastic syndromes or HSCT. (medscape.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • HSCT patients are presumed immunocompetent if they are at least 24 months post-HSCT, are not receiving immunosuppressive therapy, and do not have graft- versus-host disease (GVHD). (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • and phase mended strategies for preventing OIs in HSCT patients. (cdc.gov)
  • Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. (smw.ch)
  • If the consensus is that cytoreduction before HSCT is necessary, the patients are eligible for the CPXSMN protocol. (sparkcures.com)
  • A study conducted at the Salvador Zubirán National Institute of Health Sciences and Nutrition found that there were no cases of active tuberculosis detected in HSCT patients. (contagionlive.com)
  • Immunocompromised patients who have received a hematopoietic stem cell transplant (HSCT) have an incidence of active tuberculosis infection that is 10 to 40 times higher than the general population. (contagionlive.com)
  • For the study, the investigators conducted a retrospective analysis of clinical data from patients who underwent a HSCT between January 2010 and December 2016 at the Salvador Zubirán National Institute of Health Sciences and Nutrition. (contagionlive.com)
  • Further, the HSCT was peripheral blood in 83 patients, bone marrow in 21, and primed-bone marrow in 21 patients. (contagionlive.com)
  • While allogeneic HSCT is the conventional curative treatment for immunodeficiency and MDS, patients with MonoMAC, because of an intact T-cell population and co-existing infection, represent a profile not generally encountered in the setting of allogeneic HSCT. (nih.gov)
  • Smart Immune's ProTcell platform is designed to reconstitute a T-cell compartment in around three months , compared with 12-18 months through the standard HSCT approach, significantly reducing the time to full immune recovery and possibly opening access to allogeneic medicine to more patients. (smart-immune.com)
  • To evaluate the rate of bacteremia and the presence of fluoroquinolone resistance in pediatric patients with AML, with relapsed ALL, or undergoing HSCT who are receiving levofloxacin prophylaxis compared with no prophylaxis. (jhoponline.com)
  • Overall, 42% of patients who received levofloxacin underwent HSCT compared with none of the patients in the control group. (jhoponline.com)
  • 2 In addition, on average, approximately 750 pediatric patients undergo allogeneic hematopoietic stem cell transplant (HSCT) and nearly 500 patients undergo autologous HSCT each year. (jhoponline.com)
  • Data were collected between March and September of 2016, through the evaluation of the medical records of 43 patients who underwent HSCT and developed some type of psychological distress. (bvsalud.org)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma. (wikipedia.org)
  • As well as, HSCT is a therapy choice for sure blood-related illnesses, together with lymphoma , leukemia , and sickle cell illness . (getnom.net)
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (medscape.com)
  • Data of 58 113 HSCTs (allogeneic: 63% vs autologous: 37%) performed between 1986 and 2006 by 432 transplant teams were collected. (nus.edu.sg)
  • The increase in allogeneic HSCTs is greater than in autologous HSCTs. (nus.edu.sg)
  • This post is about basic concepts of conditioning regimens in allogeneic HSCT. (org.in)
  • For other cancers such as acute myeloid leukemia, though, the reduced mortality of the autogenous relative to allogeneic HSCT may be outweighed by an increased likelihood of cancer relapse and related mortality, so the allogeneic treatment may be preferred for those conditions. (wikipedia.org)
  • 12 months after completion of therapy) may be cured with conventional therapy, those with progressive disease or early relapse (3-12 months) are considered candidates for autologous HSCT. (nih.gov)
  • Short time to relapse and refractory disease at the time of autologous HSCT remain the most important risk factors. (nih.gov)
  • Salvage therapy options include further chemo-radiotherapy and autologous or allogeneic haematopoietic SCT (HSCT). (nih.gov)
  • First, the use of autologous hematopoietic stem cells for gene therapy obviates the need for a matched bone marrow donor since each individual would serve as his or her own bone marrow stem cell donor. (nih.gov)
  • Second, the use of the patient's own bone marrow cells for gene replacement does not result in graft-versus-host disease (GVHD), a major complication of current allogeneic transplant. (nih.gov)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
  • The major focus is on autologous HSCT (aHSCT), used in MS for over two decades and currently the fastest growing indication for this treatment in Europe, with increasing evidence to support its use in highly active relapsing remitting MS failing to respond to disease modifying therapies. (ox.ac.uk)
  • An important barrier to HSCT has been the inability to secure a suitable donors. (medscape.com)
  • It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin). (wikipedia.org)
  • Allogeneic HSCT carries significant risks such as rejection of the graft, infection, graft versus host disease (GVHD), and potential long-term side effects, translating into a 50% morbidity and mortality rate at 3 years post HSCT. (smart-immune.com)
  • Autologous HSCT requires the extraction (apheresis) of hematopoietic stem cells (HSCs) from the patient and storage of the harvested cells in a freezer. (wikipedia.org)
  • Third, use of autologous hematopoietic stem cells would be expected to enhance immune reconstitution after transplant. (nih.gov)
  • The wholesome stem cells both come from the individual (autologous) or one other individual (allogeneic). (getnom.net)
  • In addition, we perform HLA-haploidentical HSCT, including HCT with post-transplant cyclophosphamide (PTCY) for non/less-malignant hematological diseases, and T-cell replete HSCT for advanced leukemia. (opho.jp)
  • In chronic myeloid leukemia (CML), HSCT which is once the mainstay for cure is now largely supplemented by molecularly targeted therapy. (longdom.org)
  • Infection and graft-versus-host disease are major complications of allogeneic HSCT. (wikipedia.org)
  • The biological questions with MonoMAC center around whether the individual leukocyte compartments that are lost in MonoMAC (B-lymphocytes, NK cells, and monocytes) will be constituted with HSCT, and whether the residual recipient T-lymphocytes will represent an impediment to engraftment. (nih.gov)
  • We are evaluating whether allogeneic HSCT can reconstitute normal hematopoiesis in MonoMAC and reverse the hematological abnormalities in MDS, if MDS is present at the time of transplant. (nih.gov)
  • Smart Immune is the first company to develop thymus-empowered allogeneic T-cell therapies and advance them into clinical testing through its T-cell progenitor platform, ProTcell. (smart-immune.com)
  • ProTcell is Smart Immune's thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, aimed at enabling next-generation allogeneic T-cell therapies for all. (smart-immune.com)
  • The ProTcell platform has the potential for enabling a broad range of future applications including CAR ProTcell for allogeneic, long-lasting, targeted immuno-oncology therapies. (smart-immune.com)
  • The median time from tositumomab/iodine-131tositumomab therapy to HSCT was 554 days (range: 77-2,893 days). (cancernetwork.com)
  • Why is a therapy like HSCT vital for individuals with secondary progressive MS? (getnom.net)
  • Changes in both HSCT and non-HSCT therapy have modified the indications and applicability of HSCT over time. (longdom.org)
  • PHASES OF IMMUNE RECOVERY specialists, HSCT unit and clinic staff, and public health pro- fessionals. (cdc.gov)
  • Allogeneic HSCT should only be considered where potential risks are justified. (ox.ac.uk)
  • Compared with other immunomodulatory treatments, HSCT is associated with greater short-term risks and requires close interspeciality collaboration between transplant physicians and neurologists with a special interest in these neurological conditions before, during and after treatment in accredited HSCT centres. (ox.ac.uk)
  • The WHO age-sex standardized HSCT rates for the entire country were 153.3 HSCT/10 million inhabitants (95% CI 141.7 −165.8) in 2009 and 260.1 HSCT/10 million inhabitants (95% CI 245.5−275.5) in 2018. (bvsalud.org)
  • Method: We aimed to evaluate the temporal trends in HSCT transplant rates in Argentina. (bvsalud.org)
  • The total number of HSCT was 30 in 2020. (opho.jp)
  • Of the 21 allogeneic HSCT in 2020, 20 were transplanted using RIC. (opho.jp)
  • The total number of autologous and allogeneic HSCT was 1043 between 1991 and the end of 2020. (opho.jp)
  • According to patient selection criteria, overall and disease-free survival rates after autologous HSCT are 43-95% and 31-70%, respectively. (nih.gov)
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
  • The list of diseases for which HSCT is being used is rapidly increasing, and currently numbers more than 70. (medscape.com)
  • Ganciclovir is drug of choice for prevention of CMV following autologous or allogeneic HSCT in adults, adolescents, and children. (drugs.com)